![]() |
Name |
Palmarumycin C16
|
Molecular Formula | C20H18O7 | |
IUPAC Name* |
(1'R,2'R,3'S,5'S,7'R,11'R)-spiro[2,4-dioxatricyclo[7.3.1.05,13]trideca-1(12),5,7,9(13),10-pentaene-3,6'-4,12-dioxatetracyclo[5.4.1.01,7.03,5]dodecane]-2',8',11'-triol
|
|
SMILES |
C1CC([C@]23[C@]([C@@H]1O)(O2)[C@@H]([C@H]4[C@@H](C35OC6=CC=CC7=C6C(=CC=C7)O5)O4)O)O
|
|
InChI |
InChI=1S/C20H18O7/c21-12-7-8-13(22)19-18(12,27-19)16(23)15-17(24-15)20(19)25-10-5-1-3-9-4-2-6-11(26-20)14(9)10/h1-6,12-13,15-17,21-23H,7-8H2/t12-,13?,15+,16-,17+,18-,19-/m1/s1
|
|
InChIKey |
QCIVQEKYSGBTOX-LYYLEWAKSA-N
|
|
Synonyms |
Palmarumycin C16
|
|
CAS | NA | |
PubChem CID | 10248564 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 370.4 | ALogp: | 0.4 |
HBD: | 3 | HBA: | 7 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 104.0 | Aromatic Rings: | 7 |
Heavy Atoms: | 27 | QED Weighted: | 0.591 |
Caco-2 Permeability: | -5.598 | MDCK Permeability: | 0.00003210 |
Pgp-inhibitor: | 0.008 | Pgp-substrate: | 0.984 |
Human Intestinal Absorption (HIA): | 0.341 | 20% Bioavailability (F20%): | 0.141 |
30% Bioavailability (F30%): | 0.814 |
Blood-Brain-Barrier Penetration (BBB): | 0.927 | Plasma Protein Binding (PPB): | 91.17% |
Volume Distribution (VD): | 0.58 | Fu: | 3.11% |
CYP1A2-inhibitor: | 0.052 | CYP1A2-substrate: | 0.156 |
CYP2C19-inhibitor: | 0.035 | CYP2C19-substrate: | 0.367 |
CYP2C9-inhibitor: | 0.043 | CYP2C9-substrate: | 0.06 |
CYP2D6-inhibitor: | 0.007 | CYP2D6-substrate: | 0.365 |
CYP3A4-inhibitor: | 0.052 | CYP3A4-substrate: | 0.196 |
Clearance (CL): | 10.979 | Half-life (T1/2): | 0.644 |
hERG Blockers: | 0.086 | Human Hepatotoxicity (H-HT): | 0.996 |
Drug-inuced Liver Injury (DILI): | 0.963 | AMES Toxicity: | 0.533 |
Rat Oral Acute Toxicity: | 0.774 | Maximum Recommended Daily Dose: | 0.891 |
Skin Sensitization: | 0.637 | Carcinogencity: | 0.552 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.019 |
Respiratory Toxicity: | 0.966 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003197 | ![]() |
0.784 | D06ALD | ![]() |
0.230 | ||
ENC002185 | ![]() |
0.733 | D0Q3VE | ![]() |
0.227 | ||
ENC002330 | ![]() |
0.681 | D00JRA | ![]() |
0.214 | ||
ENC003239 | ![]() |
0.681 | D0Z1FX | ![]() |
0.212 | ||
ENC003238 | ![]() |
0.626 | D0O6IZ | ![]() |
0.212 | ||
ENC001999 | ![]() |
0.625 | D01TNW | ![]() |
0.209 | ||
ENC003195 | ![]() |
0.602 | D06BQU | ![]() |
0.209 | ||
ENC003196 | ![]() |
0.570 | D0W6KM | ![]() |
0.200 | ||
ENC003194 | ![]() |
0.524 | D08CCE | ![]() |
0.200 | ||
ENC003198 | ![]() |
0.486 | D08DFX | ![]() |
0.196 |